We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office, ...

Metsera (NASDAQ:MTSR) was able to complete its initial public offering [IPO] back on February 3rd of 2025. Before taking expenses into account, it was able to generate net proceeds of about $316.2 ...

In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage biotech breaking into the obesity market, the analyst ...

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity could be "a multibillion ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

Explore Metsera stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for MTSR. Science Applications Posts Better-Than-Expected Earnings, Joins Qifu Technology ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion opportunity” for the company’s ultra-long-acting ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office ...